Navigation Links
Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
Date:12/3/2008

NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services.

Isogen has previously announced a successful first round series of capital investment and the opening of its first filling line facility in Q1 2009 to deliver on the previously unmet process, facility and capacity needs of the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment.

Pharmaceutical companies can invest over $100 million and four years to develop sterile manufacturing capacity, but are highly reluctant to take this initiative until they are certain the candidate drug will receive regulatory approval. Isogen will set a new industry standard for GMP-compliant clinical manufacturing and containment, enabling Isogen's customers to plan and execute the supply of integrated sterile clinical and small scale commercial launches of single or multiple therapeutics at the same time while dramatically reducing costs and risks that are inherently associated with other in-house and outsourced alternatives.

"Our initial-stage private financing, Delaware state government backing and follow-on funding will enable Isogen to be the best positioned firm to meet the pent-up demand in biopharma for the unmet contract filling, containment and quality standards, while significantly reducing sterile manufacturing capital costs and time-to-market for new drugs," said Les Edwards, CEO, Isogen.

Biopharma's existing paradigm of spending hundreds of millions of dollars and waiting years to build additional sterile filling capacity to address clinical and commercial capacity needs of large pipelines no longer remains a viable option. Firms have few options to address these issues, and each solu
'/>"/>

SOURCE Isogen
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Isogen Launches Major New Facility to Address Global Biopharma Demand
2. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
3. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
4. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
5. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
6. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
7. Replidyne Provides Strategic Update
8. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
11. ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ORK, Nov. 20 ,, Reportlinker.c...available in its catalogue. ,, India Medical E..., http://www.reportlinker.com/p0164658/India-M...2015.html#utm_source=prnewswire&utm_medium=pr&...,, India Medical Equipment Market Analysis and ...
(Date:11/20/2009)...ORK, Nov. 20 Reportlinker.com anno...le in its catalogue. ,, Global Markets for Ass...w.reportlinker.com/p0164742/Global-Markets-for-Ass...newswire&utm_medium=pr&utm_campaign=prnews...ion covers the U.S., 15 Countries in Europe and Ja...
(Date:11/20/2009)...Mass. and LONDON, Nov. 20 /PRNewswire-FirstCall/ -...ay announced that it has received 510(k) clearance...and CE Mark approval to market its WallFlex® ...f malignant esophageal strictures (obstructions) c...-resectable esophageal cancer. ,, (Photo: ht...
Breaking Medicine Technology:Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4FDA Approves Valcyte 28R 29 28valganciclovir hydrochloride 29 to Prevent Cytomegalovirus 28CMV 29 Disease in Pediatric Patients Who Receive Heart or 55660 1FDA Approves Valcyte 28R 29 28valganciclovir hydrochloride 29 to Prevent Cytomegalovirus 28CMV 29 Disease in Pediatric Patients Who Receive Heart or 55660 2FDA Approves Valcyte 28R 29 28valganciclovir hydrochloride 29 to Prevent Cytomegalovirus 28CMV 29 Disease in Pediatric Patients Who Receive Heart or 55660 3FDA Approves Valcyte 28R 29 28valganciclovir hydrochloride 29 to Prevent Cytomegalovirus 28CMV 29 Disease in Pediatric Patients Who Receive Heart or 55660 4Think zinc 3A Molecular sensor could reveal zincs role in diseases 9732 1Think zinc 3A Molecular sensor could reveal zincs role in diseases 9732 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4
...on Aug. 5 in Nature Journal, CLEVELAND, Aug. 7 R... region within high density lipoprotein (HDL), the...ome dysfunctional within the,artery wall, inhibiti.... The work of the researchers led by Stanley Haze...Cardiology and Rehabilitation at Cleveland Clinic,...
...g Progress on Clinical and Preclinical Programs, ...mex: KAL; FWB: CA4), a developer of new drug treat...inal diseases, is pleased to provide an,update cov...s for the,second quarter of 2007. "Callisto has m...clinical programs in 2007," stated Gary S. Jacob, ...
Other Medicine Technology:Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 2Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 3Callisto Reports on Second-Quarter 2007 Milestones 2Callisto Reports on Second-Quarter 2007 Milestones 3Callisto Reports on Second-Quarter 2007 Milestones 4
(Date:11/21/2009)... Eric J. Hall, president and chief e...America (AFA) issued the following statement regar...on as part of the new annual wellness for Medicare... Affordable Care Act" that was introduced las...PRWEB) November 21, 2009 -- Eric J. Hall, presiden...
(Date:11/20/2009)... PRINCETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - N...a Special Meeting of Shareholders will be held on ...ing is to consider approval of two special resolut...nd authorize the sale of all or substantially all ...ms provided for in the asset purchase agreement da...
(Date:11/20/2009)... Senators and Congressmen in Competi...their Health Care Vote , ...rs and congressmen running for re-election next ye...guru Charlie Cook, may come to regret voting for H..., according to a breaking Zogby International/ O&r...
(Date:11/20/2009)..., HAIFA, Israel, November 20 /PRNewswire-Firs...SL.OB), http://www.CVSLMEDICAL.COM , a leading,de...ogy, today announced that,the company,s Board of D...ns,in Europe, Canada and the Far East for its prop...icable for all angioplasty (PCTA) procedures. ,...
(Date:11/20/2009)...ial published online November 20 in the Journal o...ggerated fears and hopes that often appear in news...es guidance for both the media and journals to hel...., M.S., and Steven Woloshin, M.D., M.S., of Cente...itute for Health Policy and Clinical Practice in N...
Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2
...roduct," stated a tobacco industry memo from 1969.... muddy// the link between smoking and cancer. Now,...ducers facing dozens of potentially ruinous lawsui...yone knew but no one had proof," said Robert N. Pr...
...ow the heart gets its distinguishing shape? Shape ...alterations in cell size and shape, all of which r...nitially, the heart is an uncomplicated tube that ...Yelon, and colleagues found, by using transgenic z...
...Medicine autism experts Fred R. Volkmar, M.D., and... from 19 countries that identified an individual g...o autism in children. The findings are publish... date. The Autism Genome Project (AGP), including ...
... may not be the solution to reducing obesity among...ning selections// could prove beneficial in the ba...ue of Food Technology. Published monthly by ...d and ingredient combinations that could possibly ...
...fine, you should not forget to watch your choleste... doctors// in Boston tell healthy women. A h...ound among lipids in the bloodstream) in the blood...ool, Boston, and other researchers studied 27,937 ...
...aria Network Trust (AMANET) has secured a US$4.1mi...n health research// ethics in Africa (HRE). ...iscussion, research and publications that highligh... from the Bill and Melinda Gates Foundation would ...
Other Medicine News:Health News:Tobacco Companies Obstructed Science 2Health News:Tobacco Companies Obstructed Science 3Health News:Autism Gene Identified by Yale and Global Consortium 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: